Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 15

Results For "power"

1303 News Found

Philips unveils next-gen CT system ‘Rembra’
Technology | March 06, 2026

Philips unveils next-gen CT system ‘Rembra’

Designed for intense clinical environments, Rembra can handle up to 270 exams per day


Moderna strikes $950 million global settlement with Arbutus & Genevant, clears legal hurdles for vaccine pipeline
News | March 05, 2026

Moderna strikes $950 million global settlement with Arbutus & Genevant, clears legal hurdles for vaccine pipeline

Moderna will appeal to the Federal Circuit to assert that its government-contractor immunity limits liability under federal law


Merck’s KEYTRUDA & WELIREG combo shows breakthrough results in kidney cancer trial
Clinical Trials | March 03, 2026

Merck’s KEYTRUDA & WELIREG combo shows breakthrough results in kidney cancer trial

Merck emphasized the broader significance of the findings


AbbVie’s Risankizumab shows strong results in hard-to-treat Crohn’s disease patients
Clinical Trials | March 03, 2026

AbbVie’s Risankizumab shows strong results in hard-to-treat Crohn’s disease patients

This study evaluated a difficult-to-treat Crohn's disease patient population


FDA nod to YUVIWEL, first once-weekly treatment for kids with achondroplasia
News | March 03, 2026

FDA nod to YUVIWEL, first once-weekly treatment for kids with achondroplasia

Achondroplasia, a rare genetic disorder, causes skeletal dysplasia and often increases the risk of muscular, neurological, and cardiorespiratory complications


SEOPRO stuns pharma leaders with AI-driven portfolio management at EBMPPPM 2026
Digitisation | March 02, 2026

SEOPRO stuns pharma leaders with AI-driven portfolio management at EBMPPPM 2026

During live demonstrations, industry leaders highlighted SEOPRO’s ability to spot portfolio risk, execution bottlenecks, and decision delays early—before they escalate into costly program disruptions


Merck’s KEYTRUDA shows significant survival boost in platinum-resistant ovarian cancer
Clinical Trials | February 28, 2026

Merck’s KEYTRUDA shows significant survival boost in platinum-resistant ovarian cancer

KEYTRUDA had previously met its primary endpoint of progression-free survival in all patients


Eli Lilly and Incyte score key win for teens with severe alopecia areata in Europe
News | February 28, 2026

Eli Lilly and Incyte score key win for teens with severe alopecia areata in Europe

AA, a chronic immune disease, can cause extensive and unpredictable hair loss


Eli Lilly’s orforglipron outshines oral semaglutide in landmark diabetes trial
Clinical Trials | February 28, 2026

Eli Lilly’s orforglipron outshines oral semaglutide in landmark diabetes trial

The results, published in The Lancet, showed orforglipron delivered significantly greater reductions in both A1C and body weight across primary and key secondary endpoints


Synthekine teams up with Merck to test breakthrough lung cancer combo
Biotech | February 28, 2026

Synthekine teams up with Merck to test breakthrough lung cancer combo

The partnership will focus on the ongoing SYNERGY-101 randomized Phase 2 trial for first-line